CI Falkson

2.6k total citations
15 papers, 231 citations indexed

About

CI Falkson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, CI Falkson has authored 15 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in CI Falkson's work include Cancer Treatment and Pharmacology (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (7 papers). CI Falkson is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (7 papers). CI Falkson collaborates with scholars based in United States and Canada. CI Falkson's co-authors include Tarun Arora, Elizabeth Delzell, Michael A. Morrisey, Nalini Sathiakumar, Justin Blackburn, Victoria Chia, Meredith L. Kilgore, James B. Gerstner, David Cella and Scott Wadler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Prostate Cancer and Prostatic Diseases.

In The Last Decade

CI Falkson

14 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
CI Falkson United States 5 189 132 84 59 19 15 231
L. D. Castel United States 3 307 1.6× 191 1.4× 128 1.5× 146 2.5× 16 0.8× 8 362
Şeyda Gündüz Türkiye 9 185 1.0× 76 0.6× 17 0.2× 47 0.8× 31 1.6× 15 251
Naoki Ashida Japan 9 201 1.1× 66 0.5× 19 0.2× 77 1.3× 24 1.3× 15 298
S. Vasanthan United Kingdom 7 151 0.8× 183 1.4× 162 1.9× 77 1.3× 20 1.1× 11 318
L.K. Chan China 6 191 1.0× 97 0.7× 31 0.4× 164 2.8× 44 2.3× 9 359
Rasa Jančiauskienė Lithuania 9 233 1.2× 72 0.5× 12 0.1× 168 2.8× 28 1.5× 20 299
Jill Davison Australia 7 96 0.5× 52 0.4× 20 0.2× 11 0.2× 25 1.3× 9 241
Rosella Pasqualoni Italy 11 214 1.1× 132 1.0× 257 3.1× 112 1.9× 24 1.3× 13 368
Luxi Ye China 11 148 0.8× 179 1.4× 75 0.9× 26 0.4× 34 1.8× 25 280

Countries citing papers authored by CI Falkson

Since Specialization
Citations

This map shows the geographic impact of CI Falkson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CI Falkson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CI Falkson more than expected).

Fields of papers citing papers by CI Falkson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CI Falkson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CI Falkson. The network helps show where CI Falkson may publish in the future.

Co-authorship network of co-authors of CI Falkson

This figure shows the co-authorship network connecting the top 25 collaborators of CI Falkson. A scholar is included among the top collaborators of CI Falkson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with CI Falkson. CI Falkson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Miao, Jieling, A. Stopeck, Paul Thompson, et al.. (2019). Abstract P1-17-03: Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307). Cancer Research. 79(4_Supplement). P1–17. 1 indexed citations
2.
Hamilton, Erika, Rashmi K. Murthy, Cristiano Ferrario, et al.. (2018). Abstract P5-20-01: Prolonged progression-free survival (PFS) in advanced HER2+ metastatic breast cancer with or without brain metastases: A pooled analysis of tucatinib phase 1b studies. Cancer Research. 78(4_Supplement). P5–20. 4 indexed citations
3.
Ferrario, Cristiano, Erika Hamilton, Nathalie Aucoin, et al.. (2016). Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC). Cancer Research. 76(4_Supplement). P4–14. 3 indexed citations
4.
Hamilton, E.P., SL Moulder, Nathalie Aucoin, et al.. (2016). Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). Cancer Research. 76(4_Supplement). P4–14. 5 indexed citations
5.
Umphrey, Heidi, W K Bernreuter, K Bland, et al.. (2012). Abstract P3-03-03: A tri-modality imaging assessment algorithm to evaluate neoadjuvant therapy response in patients with operable breast cancer. Cancer Research. 72(24_Supplement). P3–3. 2 indexed citations
6.
Krop, IE, Julie Najita, Ingrid A. Mayer, et al.. (2011). The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.. Journal of Clinical Oncology. 29(15_suppl). 528–528. 3 indexed citations
7.
Sathiakumar, Nalini, Elizabeth Delzell, Michael A. Morrisey, et al.. (2011). Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer and Prostatic Diseases. 14(2). 177–183. 171 indexed citations
8.
9.
Nabell, Lisle, J. Carpenter, CI Falkson, et al.. (2011). Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e11048–e11048. 1 indexed citations
10.
Carpenter, J., et al.. (2010). Abstract P1-11-24: Concurrent and Sequential Bevacizumab and Preoperative Chemotherapy in the Treatment of Locally Advanced Breast Cancer: UAB 0493. Cancer Research. 70(24_Supplement). P1–11. 2 indexed citations
11.
12.
Li, Y., AF LoBuglio, Helen Krontiras, et al.. (2009). Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. Journal of Clinical Oncology. 27(15_suppl). e11566–e11566. 3 indexed citations
13.
Forero, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2009). A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 1088–1088. 2 indexed citations
14.
Krontiras, Helen, J. Carpenter, Lisle M. Nabell, et al.. (2006). Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. Journal of Clinical Oncology. 24(18_suppl). 10622–10622. 3 indexed citations
15.
Schink, Julian C., Edie Weller, David Cella, et al.. (2001). Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).. PubMed. 7(2). 155–64. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. D. Castel Breakdown of academic impact, for papers by Şeyda Gündüz Breakdown of academic impact, for papers by Naoki Ashida Breakdown of academic impact, for papers by S. Vasanthan Breakdown of academic impact, for papers by L.K. Chan Breakdown of academic impact, for papers by Rasa Jančiauskienė Breakdown of academic impact, for papers by Jill Davison Breakdown of academic impact, for papers by Rosella Pasqualoni Breakdown of academic impact, for papers by Luxi Ye
Rankless by CCL
2026